MICROORGANISM DISPLAYING ANTIGENIC PROTEIN OF THE SARS-CoV2 CORONAVIRUS
AssigneeLes Biotechnologies Ulysse Inc.
InventorsYves HURTUBISE, Genevieve LAPERRIERE
Life of this patent
Estimating the term…
Abstract
The present technology generally relates to a microorganism displaying antigenic proteins of the SARS-CoV2 coronavirus on its surface, to methods of preparing same, to composition comprising such microorganism and to methods for treatment of SARS-CoV2 related infections in subjects.
Claims46
A recombinant microorganism comprising an antigen of SARS-CoV-2 expressed on the surface of the microorganism, wherein the recombinant microorganism is capable of inducing an immune response against a SARS-CoV-2 infection in a subject.
A recombinant microorganism displaying a fusion protein at its surface, wherein the fusion protein comprises:
- i) a receptor binding portion of a SARS-CoV-2 protein, ii) a multi-epitope chimeric portion of SARS-CoV-2 proteins;
- and a membranal protein of the microorganism;
- and wherein the recombinant microorganism is capable of inducing an immune response against a epitopes related to different SARS-CoV-2 proteins infection in a subject.
A method for displaying an antigen of SARS-CoV-2 on a surface of a microorganism, the method comprising the steps of:
- (i) preparing a vector for microorganism surface display comprising a gene construct, the gene construct comprising:
- i) a microorganism membrane attachment protein;
- ii) a gene encoding for an enzymatic activity that is absent in microorganism in the wild, and iii) a gene encoding the antigen of SARS-CoV-2, wherein, when expressed, the gene construct expresses a fusion protein between the a microorganism membrane attachment protein, the gene encoding for an enzymatic activity and the antigen of SARS-CoV-2;
- (ii) transforming a microorganism host cell with the vector for microorganism surface display;
- and
- (iii) displaying the antigen of SARS-CoV-2 on a surface of the host cell.
An isolated nucleic acid molecule encoding for a fusion protein, wherein the fusion protein comprises:
- i) a receptor binding portion of a SARS-CoV-2 protein, ii) a multi-epitope chimeric portion of SARS-CoV-2 proteins;
- and iii) a membranal protein of the microorganism.
Dependencies are inferred from the claim text.